These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 30536052

  • 1. Pharmacological activation of dimethylarginine dimethylaminohydrolase (DDAH) activity by inorganic nitrate and DDAH inhibition by NG-hydroxy-L-arginine, Nω,Nω-dimethyl-L-citrulline and Nω,Nω-dimethyl-Nδ-hydroxy-L-citrulline: results and overview.
    Bollenbach A, Tsikas D.
    Amino Acids; 2019 Mar; 51(3):483-494. PubMed ID: 30536052
    [Abstract] [Full Text] [Related]

  • 2. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans.
    Chobanyan K, Thum T, Suchy MT, Zhu B, Mitschke A, Gutzki FM, Beckmann B, Stichtenoth DO, Tsikas D.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct 15; 858(1-2):32-41. PubMed ID: 17825631
    [Abstract] [Full Text] [Related]

  • 3. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
    Selley ML.
    J Affect Disord; 2004 Jun 15; 80(2-3):249-56. PubMed ID: 15207938
    [Abstract] [Full Text] [Related]

  • 4. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.
    Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS.
    Kidney Int; 1997 Dec 15; 52(6):1593-601. PubMed ID: 9407505
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
    Trocha M, Merwid-Ląd A, Chlebda-Sieragowska E, Szuba A, Pieśniewska M, Fereniec-Gołębiewska L, Kwiatkowska J, Szeląg A, Sozański T.
    Exp Gerontol; 2014 Feb 15; 50():45-51. PubMed ID: 24269305
    [Abstract] [Full Text] [Related]

  • 7. GC-MS measurement of biological NG-hydroxy-L-arginine, a stepmotherly investigated endogenous nitric oxide synthase substrate and arginase inhibitor.
    Bollenbach A, Bakker SJL, Tsikas D.
    Amino Acids; 2019 Apr 15; 51(4):627-640. PubMed ID: 30610471
    [Abstract] [Full Text] [Related]

  • 8. Dimethylarginine-dimethylaminohydrolase-2 (DDAH-2) does not metabolize methylarginines.
    Altmann KS, Havemeyer A, Beitz E, Clement B.
    Chembiochem; 2012 Nov 26; 13(17):2599-604. PubMed ID: 23125090
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Urinary Dimethylamine (DMA) and Its Precursor Asymmetric Dimethylarginine (ADMA) in Clinical Medicine, in the Context of Nitric Oxide (NO) and Beyond.
    Tsikas D.
    J Clin Med; 2020 Jun 12; 9(6):. PubMed ID: 32545708
    [Abstract] [Full Text] [Related]

  • 11. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B, Möller-Ehrlich K, Kress T, Kniepert J, Schwedhelm E, Böger RH, Wanner C, Sauvant C, Schneider R.
    Transl Res; 2013 Aug 12; 162(2):67-76. PubMed ID: 23707198
    [Abstract] [Full Text] [Related]

  • 12. Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II.
    Chobanyan-Jürgens K, Fuchs AJ, Tsikas D, Kanzelmeyer N, Das AM, Illsinger S, Vaske B, Jordan J, Lücke T.
    Amino Acids; 2012 Aug 12; 43(2):805-11. PubMed ID: 22075968
    [Abstract] [Full Text] [Related]

  • 13. Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: A basis for the design of specific inhibitors.
    Frey D, Braun O, Briand C, Vasák M, Grütter MG.
    Structure; 2006 May 12; 14(5):901-11. PubMed ID: 16698551
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The L-arginine/NO pathway in end-stage liver disease and during orthotopic liver and kidney transplantation: biological and analytical ramifications.
    Becker T, Mevius I, de Vries DK, Schaapherder AF, zu Vilsendorf AM, Klempnauer J, Frölich JC, Tsikas D.
    Nitric Oxide; 2009 Feb 12; 20(1):61-7. PubMed ID: 18948222
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.
    Wadham C, Mangoni AA.
    Expert Opin Drug Metab Toxicol; 2009 Mar 12; 5(3):303-19. PubMed ID: 19331593
    [Abstract] [Full Text] [Related]

  • 18. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
    Feng M, Liu L, Guo Z, Xiong Y.
    Eur J Pharmacol; 2008 Apr 14; 584(1):49-56. PubMed ID: 18342305
    [Abstract] [Full Text] [Related]

  • 19. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine.
    Yin QF, Fu SH, He P, Xiong Y.
    Atherosclerosis; 2007 Jan 14; 190(1):53-61. PubMed ID: 16533509
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.